185 related articles for article (PubMed ID: 30318083)
1. GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.
Labrada M; Dorvignit D; Hevia G; Rodríguez-Zhurbenko N; Hernández AM; Vázquez AM; Fernández LE
Semin Oncol; 2018 Jan; 45(1-2):41-51. PubMed ID: 30318083
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
4. Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside.
Dorvignit D; García-Martínez L; Rossin A; Sosa K; Viera J; Hernández T; Mateo C; Hueber AO; Mesa C; López-Requena A
Immunobiology; 2015 Dec; 220(12):1343-50. PubMed ID: 26224247
[TBL] [Abstract][Full Text] [Related]
5. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.
Casadesús AV; Fernández-Marrero Y; Clavell M; Gómez JA; Hernández T; Moreno E; López-Requena A
Glycoconj J; 2013 Oct; 30(7):687-99. PubMed ID: 23547010
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside.
Heinzelbecker J; Fauskanger M; Jonson I; Krengel U; Løset GÅ; Munthe L; Tveita A
Front Immunol; 2024; 15():1331345. PubMed ID: 38370401
[TBL] [Abstract][Full Text] [Related]
7. Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.
Fernández-Marrero Y; López-Requena A
MAbs; 2011; 3(6):528-34. PubMed ID: 22123064
[TBL] [Abstract][Full Text] [Related]
8. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.
Durrant LG; Noble P; Spendlove I
Clin Exp Immunol; 2012 Feb; 167(2):206-15. PubMed ID: 22235996
[TBL] [Abstract][Full Text] [Related]
9. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody.
Fernández-Marrero Y; Hernández T; Roque-Navarro L; Talavera A; Moreno E; Griñán T; Vázquez AM; de Acosta CM; Pérez R; López-Requena A
Mol Immunol; 2011 Apr; 48(8):1059-67. PubMed ID: 21306777
[TBL] [Abstract][Full Text] [Related]
10. Key role of a structural water molecule for the specificity of 14F7-An antitumor antibody targeting the NeuGc GM3 ganglioside.
Bjerregaard-Andersen K; Abraha F; Johannesen H; Oscarson S; Moreno E; Krengel U
Glycobiology; 2021 Dec; 31(11):1500-1509. PubMed ID: 34735569
[TBL] [Abstract][Full Text] [Related]
11. [GM3 ganglioside as melanoma specific antigen and its biological function].
Hirabayashi Y; Taniguchi M
Hum Cell; 1989 Mar; 2(1):63-9. PubMed ID: 2535260
[TBL] [Abstract][Full Text] [Related]
12. Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen.
Zheng XJ; Yang F; Zheng M; Huo CX; Zhang Y; Ye XS
Org Biomol Chem; 2015 Jun; 13(22):6399-406. PubMed ID: 25982227
[TBL] [Abstract][Full Text] [Related]
13. Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.
Piperno GM; López-Requena A; Predonzani A; Dorvignit D; Labrada M; Zentilin L; Burrone OR; Cesco-Gaspere M
Gene Ther; 2015 Dec; 22(12):960-7. PubMed ID: 26181624
[TBL] [Abstract][Full Text] [Related]
14. NGcGM3 ganglioside: a privileged target for cancer vaccines.
Fernandez LE; Gabri MR; Guthmann MD; Gomez RE; Gold S; Fainboim L; Gomez DE; Alonso DF
Clin Dev Immunol; 2010; 2010():814397. PubMed ID: 21048926
[TBL] [Abstract][Full Text] [Related]
15. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities.
Rojas G; Pupo A; Gómez S; Krengel U; Moreno E
ACS Chem Biol; 2013 Feb; 8(2):376-86. PubMed ID: 23138862
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.
Alfonso M; Lanne B; Ifversen P; Vázquez AM; Pérez R; Portoukalian J; Zeuthen J
Hum Antibodies Hybridomas; 1995; 6(3):102-12. PubMed ID: 8597625
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM3 and Its Role in Cancer.
Zheng C; Terreni M; Sollogoub M; Zhang Y
Curr Med Chem; 2019; 26(16):2933-2947. PubMed ID: 29376491
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
Hoon DS; Wang Y; Sze L; Kanda H; Watanabe T; Morrison SL; Morton DL; Irie RF
Cancer Res; 1993 Nov; 53(21):5244-50. PubMed ID: 7916649
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the acyl chain of ceramide in carbohydrate recognition by an anti-glycolipid monoclonal antibody: the case of an anti-melanoma antibody, M2590, to GM3-ganglioside.
Itonori S; Hidari K; Sanai Y; Taniguchi M; Nagai Y
Glycoconj J; 1989; 6(4):551-60. PubMed ID: 2535499
[TBL] [Abstract][Full Text] [Related]
20. Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin.
Manni M; Mantuano NR; Zingg A; Kappos EA; Behrens AJ; Back J; Follador R; Faridmoayer A; Läubli H
Front Immunol; 2023; 14():1291292. PubMed ID: 38094289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
